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Development and Alpha-testing of a Stepped Decision
Aid for Patients Considering Nonsurgical Options for
Knee and Hip Osteoarthritis Management
Karine Toupin April, Tamara Rader, Gillian A. Hawker, Dawn Stacey, Annette M. O’Connor,
Vivian Welch, Anne Lyddiatt, Jessie McGowan, J. Carter Thorne, Carol Bennett, 
Jordi Pardo Pardo, George A. Wells, and Peter Tugwell 
ABSTRACT. Objective. To develop an innovative stepped patient decision aid (StDA) comparing the benefits and
harms of 13 nonsurgical treatment options for managing osteoarthritis (OA) and to evaluate its accept-
ability and effects on informed decision making.
Methods. Guided by the Ottawa Decision Support Framework and the International Patient Decision
Aid Standards, the process involved (1) developing a decision aid with evidence on 13 nonsurgical
treatments from the 2012 American College of Rheumatology OA clinical practice guidelines; and
(2) interviewing patients with OA and healthcare providers to test its acceptability and effects on
knowledge and decisional conflict.
Results. The StDA helped make the decision explicit, and presented evidence on 13 OA treatments
clustered into 5 steps or levels according to their benefits and harms. Probabilities of benefits and
harms were presented using pictograms of 100 faces formatted to allow comparisons across sets of
options. It also included a values clarification exercise and knowledge test. Feedback was obtained
from 49 patients and 7 healthcare providers. They found that the StDA presented evidence in a clear
manner, and helped patients clarify their values and make an informed decision. Some participants
found that there was too much information and others said that there was not enough on each treatment
option.
Conclusion. This innovative StDA allows patients to consider both the evidence and their values for
multiple options. The findings are being used to revise and plan future evaluation. The StDA is an
example of how research evidence in guidelines can be implemented in practice. (First Release
September 1 2016; J Rheumatol 2016;43:1891–6; doi:10.3899/jrheum.150736)
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Osteoarthritis (OA) is the most prevalent form of arthritis
worldwide and may lead to pain, disability, sleep disturbance,
work disability, depression, and fatigue1,2,3,4,5. There is no
cure for OA, but a myriad of treatments are available to help
manage OA symptoms, including pharmacological and
nonpharmacological options6. Patients with OA may have
difficulty deciding on the optimal regimen for them, because
of the complex array of treatment options6 and the need to
weigh benefits and harms. Decisions also need to be recon-
sidered as the OA severity increases7. Similarly, healthcare
providers face challenges in providing support to patients
making decisions about their OA treatment8. These include
insufficient time to communicate the evidence or to enable
patients to clarify their values for a large number of options. 
Patient decision aids (DA) are tools that present evidence
in formats that are user-friendly and designed to prepare
patients for making decisions with their healthcare provider.
A systematic review of 115 trials of patient decision aids
shows that they improve patients’ knowledge, increase
patient participation in decision making, and are more likely
to result in choosing options that match their informed
values9. However, few DA compare a wide range of
treatment options, there is limited evidence on their
effect10,11,12, and none are available to assist patients with
OA in sifting through all of the available information by
presenting the probabilities of benefits and harms for each
option. 
The objective of our study was to develop an innovative
stepped patient DA (StDA) facilitating the comparison of
benefits and harms across 13 nonsurgical treatment options
for OA, and to assess its acceptability and effects on informed
decision making among patients with OA. 
MATERIALS AND METHODS 
Development of the StDA. The StDA was designed by a multidisciplinary
team of researchers, clinicians, and a patient representative with combined
expertise in rheumatology, rehabilitation, nursing, clinical epidemiology, DA
development, arthritis self-management, and knowledge translation, using
the Ottawa Decision Support Framework (ODSF) and following the
International Patient Decision Aid Standards (IPDAS)13. Consultations with
patients were also conducted before developing the StDA. The ODSF is one
of the most commonly used frameworks to develop DA14 (found at
https://decisionaid.ohri.ca/odsf.html). The StDA was primarily developed
for use in primary care, but could also be used in rheumatology practice to
help patients make decisions about OA therapy at the time of diagnosis, as
well as over time, as the disease progresses and new treatment options are
considered. It compares the benefits and harms of 13 nonsurgical treatment
options for OA chosen according to (1) the European League Against
Rheumatism and Osteoarthritis Research Society International OA clinical
practice guidelines’ expert panels15,16,17,18; (2) the 2012 American College
of Rheumatology (ACR) OA clinical practice guidelines6, which used the
Cochrane Collaboration methodology and the Grading of Recommendations
Assessment, Development, and Evaluation (GRADE) working group
approach19; and (3) their commercial availability in Canada and the United
States. Outcomes were chosen based on their relevance for patients with OA
according to the literature, and their inclusion in the ACR OA clinical
practice guidelines6. To improve knowledge and ensure accurate risk percep-
tions, probabilities of benefits and harms of the options were visually
summarized9,20.
Acceptability evaluation and effects on informed decision making.According
to the IPDAS, this evaluation represents the α testing of this newly
developed StDA. Face-to-face or telephone interviews were conducted with
patients with OA recruited from the Ontario Hip/Knee Arthritis Cohort, as
well as from the broader community, using newspaper advertisements in
both urban and rural areas in the Toronto region. Individuals were eligible
if they spoke and understood English and had symptomatic OA diagnosed
by their physicians. They were excluded if they were or had been on a list
for total joint replacement surgery. Canadian healthcare providers from
nursing, pharmacy, physical therapy, occupational therapy, and family
medicine with experience in OA management were interviewed.
The StDA was provided to participants and was read aloud by the inter-
viewer. As they were completing it, participants were encouraged to give
their impressions on its format and content. The interviewer also asked a
series of questions and recorded participants’ answers. Participants answered
questions on acceptability, including perceptions of clarity and balance in
presentation of benefits and harms21, and preparation for decision making22.
Participants provided information on their knowledge about the treatment
options and decisional needs based on the SURE (Sure of myself;
Understand information; Risk-benefit ratio; Encouragement) screening
test23,24. Further information on the measures can be found in the data
supplement, available online at jrheum.org. Additional open-ended questions
asked about participants’ overall impressions of the StDA, strengths and
areas for improvement, and potential helpfulness of the StDA, from patients’
and healthcare providers’ perspectives. The Flesch-Kincaid readability tests
were used to assess the readability ease and the US grade level required to
understand the StDA. 
Data analysis.All data were entered into an Excel spreadsheet and analyses
were performed using the Statistical Package for Social Statistics.
Quantitative analyses were conducted for closed-ended questions and
descriptive statistics were used to summarize the acceptability of the StDA
and its effects on informed decision making. Content analysis was used for
the open-ended question responses. A transcript of the interviews was read
and coded into themes by a team member. They were then analyzed with an
initial phase of open coding followed by a process of condensation into
overarching themes. Themes were then agreed upon by 2 team members.
RESULTS 
Components of the StDA. The StDA contained (1) a
self-assessment of severity of OA pain and disability,
designed to help patients understand the disease, assess
symptoms and their effect on the patient’s life, as well as
determine whether their current treatment management is
optimal, or if they wished to change their current treatment
plan; (2) information on the benefits, harms, and side effects
of 13 nonsurgical treatment options for OA, categorized into
5 steps or levels based on the probability of improving pain
and function versus the risk of harms/side effects; (3) a values
clarification exercise in which common reasons for choosing
an option were elicited using a 6-point importance rating
scale (0 to 5); (4) a 5-item knowledge test; and (5) a 4-item
assessment of decisional conflict.
Summary of findings tables presenting the strength and
quality of the evidence used in the StDA can be found in the
ACR OA clinical practice guidelines’ supplementary
documents6. Probabilities were determined by calculating the
absolute differences between the treatment and control
groups and were represented in pictograms of 100 faces
(Figure 1). Although the options were categorized to reflect
increasing levels of benefit and risk, patients and practitioners
are encouraged to select the options in the order reflecting
their personal circumstances, disease characteristics, comor-
bidities, and values and preferences. When evidence for
treatment benefit compared with placebo was equivocal
(equivalent to 30% of individuals with clinically reduced
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Figure 1. Visual summary of the evidence shown in the stepped decision aid. NSAID: nonsteroidal antiinflammatory drugs; TENS: transcu-
taneous electrical nerve stimulation.
pain), and there was no risk of serious harms, treatments were
included in Level 0 [e.g., chondroitin, glucosamine, capsaicin
cream, and transcutaneous electrical nerve stimulation
(TENS)]. Treatments providing small benefits of around 5%
over that of placebo and no appreciable risk of serious harm
were placed in Level 1 (e.g., exercise, healthy weight,
acupuncture, acetaminophen). Treatments with over 20% of
individuals improving and no appreciable harms were in
Level 2 (e.g., nonsteroidal antiinflammatory creams, insoles,
joint injections). Levels 3 and 4 represented treatment options
with similar benefits to Level 2, but also greater harms (e.g.,
oral nonsteroidal antiinflammatory drugs with their increased
risk of gastrointestinal bleeds and heart attacks). Level 5
consisted of a referral to a surgeon for consultation about
joint replacement. No pictogram was used for Level 5
because it was beyond the scope of this StDA. Information
about costs was not provided because they vary according to
geographic regions and patients’ insurance coverage.
However, costs would be mentioned in the values clarifi-
cation exercise. 
The methodological quality of the evidence appraised with
GRADE was indicated in the StDA. Although most options
were of high quality, some options in Level 0 (chondroitin,
capsaicin), Level 1 (healthy weight), and Level 2 (insoles)
were rated as moderate quality. Evidence for TENS in Level
0 is rated as low quality. Low or moderate quality ratings
mean that estimates are less certain and are more likely to
change with further research. The StDA has a Flesch-Kincaid
readability ease of 68.8 and has a grade level of 7.1.
Acceptability and effects on informed decision making. A
total of 49 participants (mean age 53.3 yrs) from the Ontario
Hip/Knee Arthritis Cohort (n = 26), as well as from the
broader community (n = 23), reviewed the StDA (Table 1).
These 2 groups showed similar demographic and dis-
ease-related characteristics, except for duration of OA. This
was shorter in the patients from the cohort compared to the
patients from the community [mean (SD): 9.65 (7.87) vs
14.78 (9.21) yrs; mean difference (95% CI): –5.133
(–10.043, –0.222)]. Both groups showed similar results in
acceptability of the StDA and effects on informed decision
making, and so the results of the 2 groups were merged.
Most participants (89.8%) said that the elements of the
StDA were clear, although some considered it too wordy.
Half of participants (55.6%) said that the StDA presented the
appropriate amount of information, while 40% said infor-
mation should be added and 4.4% said that there was too
much information in the StDA. Half of the participants (50%)
said that the information was slanted toward medical
therapies, 41.7% said the information was balanced, and
8.3% said it was slanted toward self-care. 
Regarding preparation for decision making, most partici-
pants (85.4%) stated that the StDA would help them consider
the benefits and harms of each option, and 83.3% of partici-
pants said that it would prepare them to talk to their doctor
about what matters to them. Participants also said that it
would help them organize their own thoughts about the
decision (77.1%) and prepare them to make a better decision
(75%). They said that it would have helped them to recognize
that a decision needed to be made (68.1%), that it would have
helped them to realize that the decision depends on what
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Table 1. Demographic and disease-related characteristics of individuals with osteoarthritis. 
Characteristics Ontario Hip/Knee Patients from the Total, n = 49
Arthritis Cohort, n = 26 Broader Community, n = 23
Sex, female, n (%) 22 (84.6) 19 (82.6) 41 (83.7)
Mean age, yrs (SD) 54.23 (11.83) 52.22 (12.09) 53.3 (11.9)
Mean disease duration, yrs (SD) 9.65 (7.87) 14.78 (9.21) 12.1 (8.8)*
Pain intensity, n (%)
None 0 (0) 0 (0) 0 (0)
Mild 10 (40) 3 (14.3) 13 (28.3)
Moderate 12 (48) 15 (71.4) 27 (58.7)
Severe 3 (12) 2 (9.5) 5 (10.9)
Extreme 0 (0) 1 (4.8) 1 (2.2)
Effect of pain on function, n (%)
None 5 (20) 0 (0) 5 (10.9)
Mild 6 (24) 3 (14.3) 9 (19.6)
Moderate 12 (48) 12 (57.1) 24 (52.2)
Severe 2 (8) 5 (23.8) 7 (15.2)
Extreme 0 (0) 1 (4.8) 1 (2.2)
Education level, n (%) 
Less than a college degree 2 (7.7) 4 (17.4) 6 (12.2)
College diploma 6 (23.1) 3 (13.0) 9 (18.4)
University undergraduate degree 14 (53.8) 12 (52.2) 26 (53.1)
University graduate degree 4 (15.4) 4 (17.4) 8 (16.3)
*p value < 0.05, from chi square test for categorical variables, and independent t test for continuous variables.
matters most to them (58.7%), and that it would be useful in
helping them to think about how involved they wished to be
in the decision (50%). Just over half of participants (57.4%)
thought that the StDA would have been useful when making
a decision about OA therapy and 55.3% would recommend it. 
The mean score on the knowledge test was 82.6% (95%
CI: 76.3%-88.8%; Table 2). According to the SURE test16,17,
84.8% of participants were clear about which benefits and
harms matter most to them, 69.2% had enough information,
64.4% had enough support to make a decision, and 60% felt
sure about the best choice for them after using the StDA. Half
of participants gave positive answers to all 4 questions of the
SURE test.
Information about participants’ currently used OA treat-
ments, values and preferences, preferred treatment option,
and confidence in following the plan are shown in the data
supplement, available online at jrheum.org. It shows that
participants mostly used low-risk treatments (e.g., exercises,
insoles, healthy weight, over-the-counter treatments) to
manage their OA. Many participants wished to avoid side
effects of medications (e.g., bleeding ulcers, heart attack) and
valued pain relief. 
Healthcare provider feedback. Seven healthcare providers,
in the fields of nursing (n = 2), pharmacy (n = 2), physical
therapy (n = 1), occupational therapy (n = 1), and family
medicine (n = 1) participated in interviews. Four of them
stated that the StDA included an adequate amount of infor-
mation, 2 said that treatment options were not described fully
enough (e.g., brand names of drugs, various types of
exercises), and 1 found that some elements of the StDA were
not described enough while others were too detailed. All 7
healthcare providers supported the potential of the StDA to
help patients consider the benefits and harms of each option,
assess what matters most to them, and prepare them for
discussion with their doctor. Six healthcare professionals said
they would recommend these for all patients; the remaining
one would recommend it only if used with guidance from a
healthcare provider.
DISCUSSION 
An StDA comparing 13 nonsurgical treatment options for OA
and guiding patients on how to clarify their values was
developed using recognized frameworks and evaluated for
its acceptability and effects on informed decision making. To
our knowledge, this StDA is the first to use a stepped
approach to presenting evidence-based information with
benefit/harm probabilities for multiple nonsurgical options
for managing OA. It presents probabilities not only for
pharmacological treatment options, but also nonpharmaco-
logical ones that are often underused but nevertheless
important for patients to manage their OA. This StDA repre-
sents an innovative way to present evidence from multiple
options presented in guidelines for use in clinical practice,
while concurrently taking into account patients’ values and
preferred option. Further, assessing evidence for quality using
the GRADE approach19 helps to make it understandable to
patients and healthcare providers25. 
Most participants found that the StDA was clear and that
it helped them to clarify their values and to make an informed
decision. To be supported through their journey with OA, it
was important for patients to be able to compare the benefits
and harms of a wide range of treatment options that may be
used over the course of the disease. As one participant said,
the StDA is a way to “walk you through a journey with OA,”
because it presents options in a logical progression. 
The clear visual presentation of evidence-based infor-
mation seems to improve knowledge about treatment benefits
and harms, which may help to prevent or correct misconcep-
tions about these options. The readability was adequate
because the IPDAS suggest that DA be written at a grade 8
level or lower.
The proportion of patients recommending the StDA was
lower than expected, indicating that future versions will need
to address issues. For example, there is too much general
information but not enough on each specific treatment option.
Patients highlighted the need for more personalized infor-
mation and decision support from a coach or healthcare
provider. These results suggest that participants in our study
may be too educated and experienced (i.e., high education
level, longer disease duration, high use of low-risk treat-
ments) to fully appreciate the value in this tool, a possibility
that is consistent with another study26. Further, it may be
difficult for patients to integrate the information presented in
probabilities to make a decision, especially when there are
many treatment options. 
Because OA management is complex and changes
according to the stage of disease, an online version of the
StDA may make it easier to deliver more layered levels of
information. Patients are at different steps in the treatment
spectrum, and so we recognize that not all of them would be
interested in seeing more detailed information for all the
options. Parsing the information about options into sections
that can be selected by the patient and healthcare provider
1895Toupin April, et al: OA stepped decision aid
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2016. All rights reserved.
Table 2. Results of the knowledge test given at the end of the decision aid.
Evaluation factors Results of Patient 
             Responses, n (%)
Knows which option has the highest chance of 
withdrawal symptoms 46 (93.9)
Knows that over time, the pain from osteoarthritis 
usually gets worse 45 (93.8)
Knows which option has the highest chance of bleeding 
stomach ulcers or heart attack 39 (79.6)
Knows that if 100 people take nonsteroidal antiinflammatory 
drug pills for 1 to 6 months, 1 person with no history of 
heart disease will have a heart attack from taking them 38 (79.2)
Knows which option has the highest chance of 
improving pain 31 (63.3)
All questions answered correctly 26 (54)
At least 3 questions answered correctly 44 (92)
will help address individual needs and reduce the complexity
of the StDA. Further, with these briefer, somewhat more
detailed patient decision aids, providing access to a
healthcare provider to review the StDA can verify under-
standing and provide the opportunity for patients to commu-
nicate their values and preferences for managing OA. 
The next steps consist of modifying the StDA according
to this feedback, and evaluating it in a real-life community
setting to monitor its effect on decision making at the time
of diagnosis as well as over time. Future studies should also
evaluate how people cope with uncertainty, especially
stemming from using probabilities. Results will need to be
evaluated among a wide variety of patients in terms of age,
education level, sex, and stages of the disease. Incorporating
feedback from patients with OA and healthcare providers in
the iterative development of this StDA will help ensure its
integration into clinical practice. 
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